Company intelligence / Profile preview

Reiley Pharmaceuticals

San Francisco, California, United Statesseamless.ai ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Reiley Pharmaceuticals is developing a novel diagnostic imaging agent that combines a selective COX‑2 inhibitor with Technetium‑99m to target and illuminate regions of overexpressed COX‑2, enabling precise identification of pain sources such as lower back pain. Their lead candidate, Technetium‑99m-RPI-T‑087, has completed or is undergoing Phase 1 clinical evaluation for safety and tolerability in osteoarthritis of the knee. The company aims to revolutionize precision diagnostics for pain by providing biomarker-based imaging drugs that can pinpoint the biological source of pain[1][3].

Therapeutic areas: Rheumatology
Modalities: Small moleculeRadiopharmaceutical
Industry: Medical Imaging

Beyond the preview

Go deeper on Reiley Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reiley Pharmaceuticals.

Explore the full profile